Mission Wealth, a national registered investment adviser, has been named No. 44 on Barron's 2026 list of Top 100 RIA Firms for the sixth consecutive year. The firm manages about $17.5 billion in assets for over 5,000 families and emphasizes comprehensive financial planning and personal client relationships. This recognition highlights Mission Wealth's steady growth, strong team, and commitment to meeting complex client needs with advanced technology and personalized service. The firm also recently refreshed its brand and website to support its expanding national presence and capabilities.
Mission Wealth's recognition among top RIA firms is presented here alongside financial sector data from Pluang as of Sep 17, 2026 20:41 WIB. Among 74 priced Financials-sector US stocks tradable on Pluang, 56 rose and 17 fell today. Western Alliance Bancorporation (WAL) gained 1.95% to USD 79.31 with a typical hold time of 3 days, contrasting with KB Financial Group (KB) which rose 1.94% to USD 130.48 and a much longer typical hold time of 32 days, while Apollo Global Management (APO) increased 1.69% to USD 126.64 with a typical hold time of 65 days.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
